Haploidentical stem cell transplantation (SCT) has opened up new possibilities in the treatment of severe hematologic disease. The use of allogeneic stem cell donors who are only matched for half of their HLA antigens (haploidentical donors) with the recipient, increases the regularly available donor pool for allogeneic hematopoietic SCT. The Second European Workshop on haploidentical SCT was organized in Perugia, Italy, by two of the major pioneers of the field, Massimo F Martelli (University of Perugia, Perugia, Italy) and Yair Reisner (Weizmann Institute, Rehovot, Israel) . What follows is an overview of some issues that were discussed during that meeting.
Clinical update of the European experience in haploidentical SCT
Thirty percent of acute leukemia patients who need an allogeneic SCT can count on an HLA-matched family donor and another 30% on a matched unrelated donor (MUD). Until recently 40% had no donor at all and would have welcomed a fully HLA haplotype-mismatched family donor. The haploidentical hematopoietic stem cell (HSC) graft has to be depleted of T cells, because otherwise the risk of severe graft-versushost disease (GVHD) is over 80%. On the other hand extensive T cell depletion can be associated with more than 50% graft failure. To overcome this problem, adequate conditioning regimens had to be developed and studies in animal models demonstrated that a large stem cell dose ('megadose') had to be delivered. What follows is an overview of some of the large clinical series presented during the meeting.
F Aversa (Perugia, Italy) gave an overview of the haploidentical SCT programme that was started in Perugia in March 1993. The first method of T cell depletion, using lectin soybean agglutinin and E-rosetting of bone marrow (BM) with peripheral blood stem cell (PBSC) collections, was adopted until 1995. Thirty-six patients received a median number of 10.8 × 10 6 CD34 + cells/kg and of 2.2 × 10 5 CD3 + cells/kg. The overall engraftment rate was 92%, acute GVHD occurred in 18% and chronic GVHD in 4% of cases. This study showed for the first time that the megadose of stem cells is a crucial factor in engraftment across the major histoincompatibility barrier. Indeed, in an earlier trial a small group of patients received the same conditioning regimen and were transplanted with T cell-depleted bone marrow alone, but none engrafted.
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From 1995 until 1997, PBSC were depleted of T cells using a combination of E-rosetting and the Ceprate device from CellPro (Bothell, WA, USA). Forty-three patients were transplanted with a median number of approximately 10 × 10 6 CD34
+ cells/kg and 2 × 10 4 CD3 + T cells/kg. At this point in the program, another important change was replacing cyclophosphamide with fludarabine in the conditioning regimen. Primary engraftment was 95%, overall engraftment 100%, there was no acute GVHD with grade higher than II and chronic GVHD occurred in 1/37 patients. Event-free survival after 5 years was approximately 25%. Adverse risk factors were advanced stage of disease, a long history of disease, documented fungal infection prior to transplant and fungal colonization at transplant.
Since 1998, the CliniMACS device from Miltenyi Biotec (Bergisch Gladbach, Germany) has been used for CD34
+ cell selection (and T cell depletion) of PBSC and as of January 1999, granulocyte colony-stimulating factor (G-CSF) is no longer administered post transplant. Thirty-two patients have been transplanted with a median number of 12 × 10 6 CD34 + cells/kg and 1 × 10 4 CD3 + T lymphocytes/kg. Engraftment occurred in 31/32 patients; there was no acute GVHD with a grade higher than II. Transplant-related mortality at 1 year was 41%. When all patients of the three program periods are taken into account, event-free survival at 7 years is 35% for patients with acute myeloid leukemia (AML) and 13% for acute lymphoblastic leukemia (ALL) patients. The relapse rates were around 70% for ALL and 25% for AML.
'Good risk' patients were identified: patients in first hematologic and cytogenetic complete remission (CR), patients in CR lasting at least 2 months while off therapy before haploidentical SCT and patients with a good performance score. In the 1995-1997 series only 16/43 patients fulfilled these criteria, as did 11/32 patients in the 1998-2000 series. If only the good risk patients are considered, event-free survival is around 50%; if only high risk first CR (CRI) and stable second CR (CRII) are taken into account, event-free survival is around 65-70% and transplant-related mortality is 10%. This brings the latest results of haploidentical SCT in 'good risk' patients in line with those of the best MUD results ever. At present, eventfree survival after haploidentical SCT does not correlate with age, but does correlate with stage of disease and with timing of transplant. ALL patients no longer carry an intrinsically bad prognosis if they belong to the 'good risk' criteria prior to transplant. Indeed, there is no difference between AML and ALL if the 'good risk' criteria are satisfied.
T Klingebiel (Tü bingen, Germany) gave an overview of 48 haploidentical SCT performed between 1995 and 2000 in pediatric patients (aged 7.8 ± 5.3 years). T cell depletion was carried out using the CliniMACS device. A median number of 19.8 × 10 6 CD34 + cells/kg and 14.5 × 10 3 CD3 + cells/kg were transplanted. Primary sustained engraftment was observed in 87.5% of patients; graft failure occurred in cases of long-last-ing severe aplastic anemia. Patients transplanted in remission did better than those transplanted while not in remission; patients transplanted for non-malignant diseases did better than those with malignant disorders. No patient with ALL, transplanted while not in remission, became a long-term survivor. Overall survival was approximately 37% at 1 year. Causes of death were mainly relapse (14 cases) and infections (viral 6 cases, fungal 2 cases). One patient with a severe combined immunodeficiency had severe (grade IV) acute GVHD. After 2 months, there are already more than 100 CD3 + T cells/mm 3 in the peripheral blood. Immune reconstitution depends on the number of CD34 + cells transplanted. After 1 year the T cell receptor repertoire normalizes, with naive T lymphocytes being produced in the thymus. T cell add-backs (2.5 × 10 4 CD3 + cells/kg) are administered only if there is evidence of increasing mixed chimerism.
W Friedrich (Ulm, Germany) presented a pediatric series of 34 patients. Conditioning was partly based on busulfan. Of the 20 patients transplanted for leukemic disorders, three are alive and well. The others died of relapse (5/20), GVHD and/or infections (9/20) or early toxicity (3/20). Fourteen patients were transplanted for non-malignant diseases (7 for osteopetrosis, 4 for aplastic anemia); 9/14 had engraftment and 8/14 are alive and well.
C Peters (Vienna, Austria) presented a series of 33 haploidentical SCT performed on 25 children. T cell depletion was carried out by positive CD34 + cell selection, using the Nexell Isolex device (Irvine, CA, USA). Patients were transplanted with a mean of 23.2 × 10 6 CD34 + cells/kg and 5 × 10 4 CD3 + T lymphocytes; no GVHD prophylaxis was given. Engraftment occurred in 25/33 transplantations, without GVHD and with a survival rate of around 50%. Half of the eight graft failures occurred after administering a non-myeloablative conditioning regimen for severe combined immunodeficiency. Six patients who initially showed graft failure, engrafted following second or third transplants. A Fasth (Gö teborg, Sweden) presented the results of haploidentical SCT performed for non-malignant disorders in children. The conditioning regimen included busulfan and cyclophosphamide. All BM collections were T cell depleted with CAMPATH-1H and autologous serum. There was survival in 9/33 patients: 4/11 with severe combined immunodeficiency, 3/11 with osteopetrosis, 0/4 with Fanconi's anemia. For many patients, marrow failure was the main factor for fatal infection.
T Zuckerman (Haifa, Israel) presented the results of haploidentical SCT performed in seven children and 15 adults. Six patients (4 adults, 2 children) are alive. Engraftment occurred in all children and in 11/13 evaluable adults. There was grade I-II GVHD in 4/22 patients. Causes of transplant-related mortality in 12/22 patients included pulmonary fibrosis (3 patients), CMV disease (2 patients), sepsis (2 patients), venoocclusive disease together with multiple organ failure (2 patients), cerebritis (1 patient) and graft failure (2 patients). Late complications included idiopathic thrombocytopenic purpura 10 months post transplant which responded only to splenectomy, cerebritis and disseminated herpes zoster disease 30-40 months post transplant.
A Nagler (Jerusalem, Israel) presented a series of haploidentical SCT that was performed in 40 patients with a median age of 22 years (range 1-54 years), 13 with ALL, 13 with AML, 11 with chronic myeloid leukemia (CML) and three with nonmalignant disease. In the malignant disease category, 30 patients had resistant disease and were in second or further relapse. Transplant-related mortality was 48%, event-free survival 16% and overall survival 21% after 2 years follow-up.
Leukemia
In the 10 patients with standard risk responsive disease, disease-free survival was around 50%. Mortality was mainly due to relapse (13 patients), graft failure (8 patients), GVHD (3 patients), pulmonary toxicity (4 patients).
J Cornish (Bristol, UK) presented a pediatric series of haploidentical SCT. Graft processing was carried out using CAM-PATH-1H in the HSC bag or using the CliniMACS device. Six out of nine ALL patients were alive, while three died due to fungus, adenovirus or relapse; 2/6 AML patients were alive, while one died of adenovirus infection and three of relapse. The survival rate of more than 50% in haploidentical SCT is comparable with that seen after MUD transplant.
New conditioning regimens
S Slavin (Jerusalem, Israel), whose group helped pioneer nonmyeloablative stem cell transplants or 'mini-transplants', gave an overview of the mechanisms that are associated with GVHD, rejection and tolerance. He reminded the audience that tolerance is easily induced in utero, if HSC are mixed between embryos. When performing an allogeneic SCT, one has to reach a balance between GVHD (which is mediated by donor T lymphocytes) and rejection (which is mediated by host T cells). There are three potential approaches: (1) to eliminate all T cells in donor and recipient; (2) to eliminate all T lymphocytes that mediate host and graft allo-rejection; (3) to induce T cell tolerance and perform later T cell addbacks. In a mouse model, transplant tolerance can be achieved after nonmyeloablative SCT, without adversely affecting graft-versus-tumor effect. Host allo-reactive T cells are first activated through contact with donor cells and then treated with alkylating agents, which leads to ablation of alloreactive T lymphocytes. Animal studies also demonstrate donor T cells can downregulate recipient T cells and vice versa. Host CD8 + T cells can decrease GVHD. There is a reciprocal relationship between cytotoxic T lymphocyte precursor frequency and minimal stem cell dose that is required for durable engraftment and tolerance.
F Aversa reported on a series of haploidentical SCT performed in elderly patients. Seven patients (5 with low blast count: 3 with AML, 2 with secondary AML; 2 patients with high blast count: 1 with ALL and 1 with CML in blast crisis) with a median age of 65 years were transplanted, after conditioning with melphalan, fludarabine, thiotepa and rabbit anti-thymocyte globulin (ATG). The scheme was tolerated reasonably well, with only one patient showing severe gastro-intestinal toxicity followed by hemorrhagic death. CD34
+ cell dose was 8.5-13.5 × 10 6 /kg, CD3 + T cell dose was 3 × 10 4 /kg in all cases. All patients engrafted well without any acute GVHD. Four out of seven patients died, one from human herpesvirus (HHV)-6 infection, one from gastro-intestinal hemorrhage, one from a Guillain-Barré syndrome and one from a lung fibrosis syndrome, possibly due to CMV disease. One patient relapsed (the ALL patient), two patients are in continuing CR. This series was extended to 11 more patients, who had been extensively treated in the past. All patients engrafted and none showed GVHD. Three patients are still alive in continuing CR; the others died of relapse, aspergillosis or of WHO grade 3 toxicity, which led to multiple organ failure.
Y Reisner raised the question of whether unrelated stem cells can be engrafted in sublethally irradiated recipients. A megadose of T cell-depleted BM can overcome major histocompatibility complex (MHC) barriers in sublethally irradiated mice. Transplantation of sca
− stem cells induces donor-type chimerism and intensity of the total body irradiation (TBI) and stem cell dose are directly correlated, ie when using a lower level of TBI, a higher quantity of HSC must be given to ensure a similar type of chimerism. These studies pertain to mice, and cannot be extrapolated to humans, since similar numbers of stem cells are not available. However, there is hope in immunological circles, that 'veto' cells -at least some of which are CD8 + -may help modulate immunological reactions. They are believed to inhibit T cell reactivity of another individual (and there is experimental evidence for this) (see also further). When using sublethal irradiation, one can hope to inhibit graft rejection by administering more donor-type veto cells and one can also imagine depleting allo-reactive GVHD-causing anti-host T cells, for instance by selective starvation of IL-2.
Stem cell processing
S Miltenyi (Miltenyi Biotec Corporation) reported on the progress of the CliniMACS device. Approved by the EU in December 1997, the device has been used for more than 4500 CD34
+ cell selections. CD34 + cell yield has been around 75% and purity around 93%. CD3
+ T cell depletion is by a 4.25-log factor, monocyte depletion by a 3.6-log factor, and CD20 + B cell depletion by a 3.4-log factor. A new development is a monoclonal antibody directed against the CD133 antigen, a new stem cell marker. This antibody ('AC133') is pending EU approval. CD133 is associated with HSC and endothelial cells and is not usually expressed on AML cells. In the future this antibody may be used for purging in autologous transplants for patients with CD34
+ CD133 − malignancies. J Kemshead (Nexell Therapeutics Corporation) reported on the new Isolex 300i solid phase technology with the V2.5 software, which allows for simultaneous positive CD34
+ cell selection and negative T cell selection. At the time of the meetings, the Food and Drug Administration (FDA) had only given approval for the positive CD34 + cell selection. When the Isolex 300i and the CliniMACS devices are compared, similar levels of CD34 + cell yield and T cell depletion are obtained with both. The Isolex device seems to have one advantage in terms of B cell depletion.
M Watts (London, UK) used the Isolex 300i device for positive CD34
+ cell separation only (thus without the additional negative T cell depletion) and compared the results with the CliniMACS device for CD34 + cell isolation. The CliniMACS device required less time and resulted in a more profound T cell depletion (3.6-log depletion for the Isolex device, vs 4.5-log depletion for the CliniMACS device), higher CD34 + cell purity but similar CD34 + cell yield, lower CD34 + cell viability (70% annexin V/propidium iodide-negative cells for the Clini-MACS device, vs 80% for the Isolex device), similar numbers of CFU-GM and lower numbers of BFU-E.
Specific tolerance induction
Y Reisner addressed the question of how escalating the CD34 + cell dose overcomes the barrier of host anti-donor cytotoxic T lymphocytes (CTL). According to some immunologists, a stem cell megadose is endowed with a veto activity. Veto cells, defined as being able to specifically prevent the development of CTL against antigens presented by the veto cells, are found within CD8
+ cells, CD4 + cells and dendritic cells. Cells with the strongest veto activity are contained within
CD8
+ cells, but CD8 + (CTL) cells can also induce GVHD. Immunological experiments show that anti-third party CTL enhance engraftment of T cell-depleted BM allografts, most probably via the veto activity of anti-third party CTL. There is evidence of target specifity, of the importance of veto/effector cell ratios and that the veto effect only works at the CTLp (CTL precursor) level. Molecules involved in the veto effect are: Fas-ligand, MHC and CD8 on the veto cell, which bind respectively to Fas, T cell receptor and MHC class 1 ␣ 3 domain on CTL effector cells. Interactions induce apoptosis via a perforin-independent mechanism: CD8 on veto cells induces apoptosis of CD8 + effector CTL via interaction with the ␣ 3 domain of MHC class 1. The hope is to engineer cells with Fas ligand and CD8 (or maybe other accessory molecules) in order to generate veto cells which will induce transplantation tolerance.
H Waldmann (Cambridge, UK) reported on inducing T cell tolerance with antibodies directed against molecules on T lymphocytes. Non-lytic anti-CD4 antibodies can lead to tolerance for skin, heart, Langerhans islands and BM grafts in naive and in primed rodents. This tolerance is transferable to other animals after bone marrow transplantation (BMT) and is mediated mainly by CD4 + T lymphocytes. Another antibody used in clinical studies to induce tolerance is CAMPATH-1H. In renal transplants a double dose of 20 mg, administered around transplantation, leads to a 2-log depletion of lymphocytes; in 31 patients treated with CAMPATH-1H, there was no evidence of overt rejection and 28/31 patients were steroid-free, receiving only low doses of cyclosporin A or tacrolimus as maintenance immunosuppression. CAMPATH-1H has also been combined with fludarabine and melphalan in the conditioning regimen for nonmyeloablative stem cell transplants. Sixty-two of the 64 patients showed a durable engraftment (one patient died before being evaluable and one rejected at day +30). Transplant-related mortality occurred in 8/64 patients, acute GVHD in five (three with grade I and two with grade II GVHD), chronic GVHD in one and relapse in 10/64 patients. In 15 patients who were similarly transplanted in nonmyeloablative conditions with HSC from a MUD, there was no GVHD and no transplant-related mortality. The use of CAMPATH-1H is now being planned as part of the preparative regimen for transplantation of cadaver donor organs.
G Wagemaker (Rotterdam, The Netherlands) presented data for the next frontier in mismatched stem cell transplants: totally mismatched stem cells in mice and in rhesus monkeys. Successful engraftment requires even higher megadoses of CD34 + cells, in the order of 20-40 × 10 6 /kg. In vivo experiments clearly showed that administering T cell antibodies could shift the conditioning radiation dose required to achieve a 50% partial chimerism. The very steep relationship between radiation dose and chimerism was not changed by anti-T cell antibodies. In these totally mismatched stem cell transplant experiments in monkeys, engraftment was achieved using TBI alone in conjunction with CD3 monoclonal antibodies.
C Craddock (Birmingham, UK) presented his data on nonmyeloablative stem cell transplants, using T cell-depleted stem cell grafts. As GVHD remains a problem in the so-called 'mini-transplants', T cell depletion was performed using the Clinimacs or Isolex device for matched related and in MUD mini-transplants. Conditioning was with fludarabine and busulfan or melphalan. Patients also received cyclosporin A with or without ATG. Median number of stem cells administered was 4.2 × 10 6 /kg CD34 + cells, mean number of T lymphocytes was 0.9 × 10 4 CD3 + cells/kg. Donor lymphocyte infusions (DLI) were administered, if there was less then 100% lympho-cyte chimerism at day +90. Fourteen of the 15 patients engrafted (one MUD transplant did not engraft). No patient developed GVHD worse than grade II. Eight out of 15 patients reached a complete remission and 7/15 patients are alive with a durable myeloid and lymphoid chimerism. During the discussion it was remarked that a higher degree of graft failure had occurred in a similar series performed in Adelaide, Australia. The difference in engraftment rates might have been due to the inclusion in the UK series of more patients who had been more heavily pre-treated with chemotherapy before the mini-transplant. This is associated with a higher degree of immunosuppression, which presumably leads to a higher degree of engraftment, even when transplanted with T celldepleted grafts.
E Zappone (Milan, Italy) reported that IL-10 induces alloantigen-specific anergy in CD4 + T lymphocytes, which cannot be reversed by adding IL-2 or anti-CD28 monoclonal antibodies, is long-lasting and reduces the frequency of CTLp. The alloreactive T lymphocytes retain their capacity to react to other 'regular' antigens. This will lead to a clinical protocol: after haploidentical SCT, adoptive immunotherapy will be started using T lymphocytes that have been tolerized ex vivo with IL-10.
Graft-versus-leukemia: DLI, natural killer (NK) alloreactivity
HJ Kolb (Munich, Germany) reported on the current clinical status of graft-versus-leukemia (GVL). This is effective in relapse, where DLI leads to a CR of CML in up to 80% of cases, of AML in around 25% and of ALL in around 15% of cases. This CR-inducing effect is sustainable following DLI, especially in CML. Effectors of the GVL effect are: (1) CD4 + T lymphocytes interacting with HLA class II molecules on target cells; (2) CD8 + T lymphocytes reacting with HLA class I molecules on target cells, including leukemia-specific antigens, minor histocompatibility antigens (whether present either on only hematopoietic cells or on all cells); (3) NK cells reacting with, for instance, malignant cells that lack HLA-C antigens. Possible mechanisms for immune escape of leukemia from the GVL effect include: (1) low levels of expression of (a) class I or class II HLA antigens on leukemic cells; (b) adhesion molecules, eg LFA-3, ICAM; and (c) co-stimulatory molecules (CD80,CD86); (2) failure to present minor histocompatibility antigens or leukemia-specific antigens; (3) failure to produce pro-inflammatory cytokines (eg TNF-␣, interferon-␣, interferon-␥); (4) production of inhibitory cytokines (IL-10, TGF-␤); (5) failure to express Fas or expression of non-functional Fas; (6) inhibition of T cells by expression of Fas ligand.
M Colonna (Basel, Switzerland) gave an overview on NK cell reactivity. NK cells recognize their target via activatory receptors (KAR) and inhibitory receptors (KIR). Recognition of target cell molecules by KIR inhibits NK killing; lack of recognition allows for killing. KIR are part of a family of receptors with immunoreceptor tyrosine-based inhibitory motifs (ITIM) which recruit SH2-containing phosphatases. KAR have immunoreceptor tyrosine-based activating motifs (ITAM) which recruit tyrosine kinases. KIR are Ig-like receptors. They recognize epitopes on HLA-C, -A, -G and -B. NK cells express surface receptors for different HLA class I polymorphisms. Some NK clones express different KIR with different specificity. NK cells lyse target cells derived from allogeneic donors, although the majority of clones is not alloreactive. KAR are part of the CD2 subfamily of the Ig superfamily of receptors. One Leukemia example of KAR is 2B4. There is an X-linked lymphoproliferative disorder that is caused by a failure of 2B4 to recruit SLAM-associated protein (SAP)-1 or -2 in NK cells. This is due to a deficit of SAP in the NK cells (SAP, an adapter protein for the signal transduction of certain receptors, is expressed on NK cells and T lymphocytes, but not on myeloid cells or on B lymphocytes). In this disorder, where there is an inability to control Epstein-Barr virus (EBV) infection, due to a deficit of NK and T cell-mediated cytotoxicity and of developing an EBV-specific antibody response, SAP-deficient NK cells are incapable of recognizing CD48-expressing cells (2B4 recognizes CD48 on target cells). EBV-infected cells overexpress CD48, but cannot be controlled by SAP-deficient NK cells. It seems that the function of KAR is to recognize 'alert' molecules: in stress conditions these may be heat shock proteins; in viral infections they may include CD48 as in EBV-infected cells. NK/T cells are a heterogenous population; different receptors are present on different subsets: some subsets have KIR, some have KAR, and usually not all of them are present on the same cells.
A Velardi (Perugia, Italy) presented data on the role of NK alloreactivity in transplant conditioning and in control of leukemic relapse. Generally, the major problem in HLA-matched transplant is GVHD. Disease targets for NK alloreactivity are LFA-1+ ALL (the majority of ALL in adults is LFA-1-though), AML, CML, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma, CD34
+ cells, activated T lymphocytes, EBV + cell lines. Normal tissues are not targets for NK alloreactivity. Human alloreactive NK clones can rescue NOD-SCID mice from human EBV-transformed lymphoblastoid cell lines; they can also eradicate human AML in NOD-SCID mice. KIR epitope mismatch in the graft-versushost direction is associated with a significantly lower proportion of relapses after haploidentical SCT for AML and CML. This is not the case for ALL. This means that KIR epitope mismatch (HLA-C group 1 or 2, Bw4) in the graft-versus-host direction is likely to become a major selection criterion of a donor. KIR epitope mismatch in the graft-versus-host direction also seems to be associated with a lower proportion of graft rejection after haploidentical SCT performed following lethal conditioning. New, less harsh conditioning regimens for haploidentical SCT may become feasible by adding more NK cells during or after transplantation without compromising engraftment. Experiments in mice show that adding NK cells does not lead to GVHD; alloreactive NK cells also promote hematopoietic engraftment in non-lethally conditioned hosts. It seems that at least in mice, host-reactive (against the donor or against third party) NK cells are associated with enough immune suppression for engraftment, without causing GVHD in non-lethally conditioned MHC-matched or MHC-mismatched hosts. After haploidentical SCT the number of NK cells reaches normal levels after 2 or 3 weeks. This may be due to de novo generation starting from HSC.
B Glass (Kiel, Germany) presented data showing that in MHC-mismatched BMT, GVL depends on NK cells and T lymphocytes. Leukemia-free survival following T cell-depleted BMT is higher when IL-2-activated NK cells are added. The following mechanisms are involved in NK lytic activity: release of cytotoxic granules and the perforin-mediated secretory pathway which seems to be the most important for NK activity. It leads to an ion efflux out of target cells, causing apoptosis. Cytokine activation of NK cells, for instance by IL-2, can induce significant cytotoxic activity on targets that are otherwise resistant to NK lytic activty.
C Peters (Vienna, Austria) presented her pediatric series of DLI after haploidentical SCT. Twelve patients received DLI because of delayed T cell engraftment, increasing recipient chimerism and/or relapse. The first DLI contained under 5 × 10 4 T cells/kg. DLI were repeated with escalating doses at intervals of 2-6 weeks, with careful monitoring of chimerism and GVHD. No preventive immunosuppression was given and only mild GVHD was observed in 3/12 patients. DLI was associated with complete chimerism in 10/12 patients and in complete remission in three patients who had relapsed.
Prophylaxis and therapy of infections: immune reconstitution and adoptive immunotherapy
M Lowdell (London, UK) presented his data on depletion of alloreactive cells using anti-CD69 monoclonal antibodies. In a murine model and in vitro with human cells, it seems that alloreactive cells (that can cause GVHD) can be depleted without depleting the non-alloreactive T cells that have an essential role in fighting infections. First, T lymphocytes are activated with allogeneic cells, then depleted of CD69 + activated T cells. Cells treated in this way do not cause GVHD in 12/14 recipient mice. In the in vitro human equivalent, the CD69
− non-alloreactive cell fraction retains activity against cytomegalovirus (CMV) and EBV.
L Romani (Perugia, Italy) gave an overview of the molecular mechanisms of innate immunity. The innate immune system allows discrimination using Toll-like receptors (TLR), mannose receptors, CR3 receptors, scavenger receptors. The innate immune system is activated through PAMPs (pathogen-associated molecular patterns) and PRRs (pathogen recognition receptors). Examples of PAMP are TLR-4, CD14, that act as receptors for bacterial lipopolysaccharide. Once innate immunity is activated, instructive mechanisms follow (expression of costimulatory molecules, chemokines and cytokines), to activate the adaptive immune system with a T helper (Th) response which starts from T helper precursors (Thp), and differentiates into Th1 and Th2. E Roosnek (Geneva, Switzerland) gave an overview of T cell reconstitution patterns after T cell-depleted allogeneic SCT. There are no CD4
− naive T cells during the first months after SCT. The T cell repertoire, as analyzed by CDR3 spectrotyping, is limited. After T cell-depleted transplants, the majority of patients have CD4
+ T cells that are CD45RO + for around 6 months, indicating that the limited T cell repertoire is generated by peripheral expansion of T cells with a memory phenotype, rather than by de novo generation through the thymic pathway. Loss of T cell memory following T cell-depleted SCT is due to the loss of T cells reacting against recall antigens. Response to tetanus toxoid vaccination correlates with the (residual) thymic activity, as measured by the re-appearance of CD4 + CD45RA + RO − naive T cells. Because antigenspecific T cells must be reconstituted from the new repertoire, serial vaccination boosts might be necessary for a primary response, but vaccination will not be useful before the CD4 +
CD45RA
+ naive T lymphocytes appear. These data also indicate that the thymus is still active in adult patients.
H Einsele (Tü bingen, Germany) presented a protocol that is used in Tü bingen for chronic CMV infections after haploidentical SCT. Late-onset CMV disease (following day +100 post transplant) is correlated with lack of CMV-specific lymphoproliferative reponse. Patients who were chronically infected with CMV, despite at least 4 weeks specific antiviral treatment, were analyzed for availability of donor-derived CMV-reactive T cell lines. These cultured T cell clones were administered and seemed to clear CMV in the majority of cases. CMV clearing was less than optimal in two cases and was associated with decreased telomer length in cultured T cells, indicating a limited lifespan. In some cases, dendritic cells were also observed to be infected by CMV.
M Cavazzana-Calvo (Paris, France) reported on a phase I/II study. Haploidentical SCT, using CD34
+ cells isolated with the CliniMACS device, is performed in children with disorders of the hematopoietic system, after conditioning with ATG, busulfan and cyclophosphamide. Median age of transplanted patients was 17 months (range 1-40 months). Allogeneic donor T cells are administered at day +14 or later post transplant, after incubation with recipient PBMC followed by treatment with toxin-conjugated anti-CD25 monoclonal antibody. The aim is to return only non-alloreactive donor T cells; 1-6 × 10 5 CD3 + /kg were added back. Engraftment occurred in 12/13 patients, acute GVHD (grade 2 or less) in 4/13. Seven of the 13 patients survive. Causes of death were veno-occlusive disease, infections (varicella zoster virus, staphylococcus), relapse and pulmonary hypertension. There was no early or late toxicity due to the non-alloreactive T cell add-back, which helped reach a peripheral blood CD3
+ cell count of Ͼ300/l sooner.
R Maccario (Pavia, Italy) reported on induction of anergy, by blocking the B7/CD28 costimulatory signal with CTLA4-Ig. In these in vitro studies, peripheral blood mononuclear cells (PBMC) from donor and recipient were incubated for 5 days in the presence of CTLA4-Ig + cyclosporin A. Cells were tested for alloreactivity by limiting dilution assays. Incubation in the presence of CTLA4-Ig + cyclosporin A was more effective than CTLA4-Ig alone in reducing the frequency of responsive cells (CTLp and IL-2-producing cells). There was no significant change in CTLp directed against EBV, CMV or autologous leukemic targets. This is the basis for a clinical trial which will administer T cells anergic to allo-antigens, but still reactive to, for instance, CMV and leukemic cells, on day +25 after haploidentical SCT. The Boston group follows a similar procedure, but only with CTLA4-Ig and without cyclosporin A in the ex vivo reaction mixture.
A Velardi reported that G-CSF, when administered post transplant in order to raise the leukocyte count, induces partial immunodeficiency. It has recently become clear that G-CSF promotes Th2 response and blocks IL-12 production by antigen-presenting cells in vitro and in vivo, the latter following stem cell mobilization. Antifungal response is also decreased. The protocol in Perugia has consequently been changed and now no G-CSF is administered after haploidentical SCT. This did not have a deleterious effect on engraftment and indeed is associated with an improved CD4 + T cell recovery, with a Th1 pattern and with quicker recovery of IL-12 production (1 month post transplant as compared to more than 1 year if G-CSF is administered). Granulocyte-macrophage colony-stimulating factor (GM-CSF) does not seem to have the immunosuppressive effect of G-CSF and its administration following haploidentical SCT is associated with a 3 to 8-fold increase in frequency of pathogen-specific T cells.
An additional approach to the profound post-transplant T cell deficiency, is to grow donor CD4 + T cell clones directed against Aspergillus fumigatus and CMV in vitro. The T cell clones are screened for cross-reactivity to host allo-antigens by mixed leukocyte reactions (MLR). Non-host-reactive clones, presumably devoid of GVHD potential are pooled and infused into recipients at a dose of 2-4 × 10 5 /kg on day +15 after transplant. Infusions seem to be associated with a better response against CMV and/or Aspergillus but it is not yet clear whether this is associated with a decrease of (late) CMV antigenemia or with better outcome.
Conclusions
In many reports haploidentical SCT has been tried out for very bad risk cases, as 'a last chance' treatment just like sibling HLA fully matched allogeneic SCT around 20 years ago. However it is already clear that: (1) hematological engraftment can be achieved with megadoses of CD34 + cells after immunoand myeloablative conditioning regimens; (2) GVHD can be prevented by extensive T cell depletion of the graft; (3) some patients with advanced stage disease have been, and will be, cured with haploidentical SCT, whereas they would have died because of unavailability of a MUD SCT. As in the past, the emphasis is shifting from transplanting patients in catastrophic conditions, to patients with high risk CRI or CRII. Analysis of outcome in the adult patients transplanted in Perugia and the pediatric patients in Tuebingen and Bristol shows event-free survival compares favorably with reports in matched unrelated transplants.
Consequently, instead of being a last chance effort, haploidentical SCT will probably become a more elective procedure, as has happened in the past with other types of allogeneic SCT. Haploidentical SCT may even come to replace MUD or cord blood transplants, at least in part, as allogeneic transplant of choice for patients who lack a HLA-matched family donor.
Potential major problems associated with extensively T celldepleted haploidentical SCT are, as might be expected, infection-related mortality due to the poor immunological reconstitution and relapse of the original disease. A possible solution to the latter can be discerned in donor-versus-recipient NK cell alloreactivity, a biological phenomenon unique to mismatched transplants. Indeed, a KIR epitope (HLA-B and HLA-C) mismatch in the graft-versus-host direction seems to be Leukemia associated with fewer relapses in AML. When more than one haploidentical family donor is available, HLA typing should be used to select the potentially NK alloreactive donor. Another result of insight into T and NK cell biology, is that less toxic conditioning regimens may become possible, even in the mismatched setting. In murine models after nonmyeloablative conditioning protocols, like those used in so-called 'mini'-transplants, the infusion of NK cells together with the graft allows engraftment of a mismatched transplant without inducing GVHD. Another interesting approach to enhance engraftment is the use of donor CTL directed against a third party. These CD8 + cells induce a strong veto activity without causing GVHD.
All clinical reports presented at this workshop emphasized the high incidence of infection-related deaths. This is due to the type of patients who were transplanted -most were in advanced stage disease, had been heavily pretreated and were colonized at time of transplant -and to the slow immunological reconstitution which is inevitably related to the extensive T cell depletion of the inoculum. However, if patients are transplanted in earlier stages of the disease, such as was done in some cases in the Perugia and Tü bingen experience, the incidence of infection-related deaths is similar to that which is reported in patients receiving matched transplants. Moreover, suspending post-transplant G-CSF treatment improves immunological reconstitution and further benefits might be derived from donor T lymphocytes specifically directed against CMV antigens and ex vivo depleted of alloreactivity. Another alternative would be to induce ex vivo anergy to alloantigens, while preserving 'normal' T cell reactivity against infectious agents and hopefully also against tumors.
In conclusion, up to 10 years ago haploidentical SCT was, in certain clinical circles, considered a highly irresponsible procedure, but now it has saved some patients from certain death and is currently entering the mainstream of hematological treatment. It is to be hoped that the future 10 years from now will look even brighter.
